In vivo pre-activation of monocytes in patients with axial spondyloarthritis by unknown
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 
DOI 10.1186/s13075-015-0694-2RESEARCH ARTICLE Open AccessIn vivo pre-activation of monocytes in
patients with axial spondyloarthritis
Kristina Conrad1, Peihua Wu2, Joachim Sieper1,2 and Uta Syrbe1,2*Abstract
Introduction: Innate immune responses, including monocyte functions, seem to play an important role in the
pathogenesis of axial spondyloarthritis (axSpA). Therefore, we characterized the phenotype and functional state of
monocytes of patients with axSpA.
Methods: Fifty-seven patients with axSpA, 11 patients with rheumatoid arthritis (RA), and 29 healthy controls were
included in the study. We determined the percentage of classic, intermediate, and non-classic monocytes according
to CD14 and CD16 expression and the expression of Toll-like receptor (TLR) 1, 2, and 4 in whole blood by flow
cytometry. The percentage of monocytes producing interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNFα),
IL-12/23p40, and IL-1 receptor antagonist (IL-1ra) was detected by flow cytometry after stimulation of whole blood
without and with different TLR and nucleotide-binding oligomerization domain ligands—i.e., lipopolysaccharide
(LPS), fibroblast-stimulating lipopeptid-1, PAM3CSK4, and muramyl dipeptide (MDP)—for 5 h. IL-10 production was
measured after 18 h of stimulation in supernatants by enzyme-linked immunosorbent assay.
Results: In patients with axSpA but not patients with RA, we found higher frequencies of classic monocytes than
in controls (median of 90.4 % versus 80.4 %, P < 0.05), higher frequencies of monocytes spontaneously producing
IL-1beta and IL-1ra (P < 0.05), and a higher percentage of monocytes producing IL-1beta after MDP stimulation
(P < 0.05). Elevated cytokine production was confined to axSpA patients under conventional therapy (non-steroidal
anti-inflammatory drugs) and not found in patients under TNFα inhibitor treatment. The LPS-induced production
of IL-6 and IL-10 was lower in axSpA patients compared with controls (P < 0.05). Monocytic TLR expression was
unaffected in patients with axSpA.
Conclusion: Enhanced spontaneous and MDP-induced cytokine secretion by monocytes suggests in vivo
pre-activation of monocytes in axSpA patients under conventional therapy which is reverted under TNF
inhibitor treatment.Introduction
Axial spondyloarthritis (AxSpA) is the prototypic form
of spondyloarthritis, a group of related diseases compris-
ing AxSpA, reactive arthritis, arthritis related to inflam-
matory bowel disease, psoriasis, and uveitis [1]. AxSpA,
nowadays subdivided into non-radiographic axSpA and
ankylosing spondylitis (AS), is characterized by inflam-
mation within the axial skeleton, predominately of the
sacroiliac joints [1].* Correspondence: uta.syrbe@charite.de
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creativecommons.org/publicdomain/zero/1.0/The pathogenesis and triggers of inflammation in axSpA
are still unclear. AxSpA is strongly associated with the
major histocompatibility complex (MHC) class I molecule
HLA-B27; however, the involvement of CD8 T-cell re-
sponses could not be proven so far. In fact, in the HLA-
B27 transgenic rat model, CD8 T cells are dispensable for
disease induction [2]. Apart from presenting specific anti-
gens to CD8+ T cells, HLA-B27 has the capability to in-
duce endoplasmic reticulum stress [3]. In innate immune
cells, this can trigger cytokine responses or modify the re-
sponsiveness of these cells to other stimulants, suggesting
that innate immune functions might play a role in the
pathogenesis of axSpA.
Monocytes belong to the innate, first-line defence against
infections. They recognize bacterial structures by patternrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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and nucleotide-binding oligomerization domain (NOD)-
like-receptors. Ligation of TLR or NOD receptors rapidly
triggers production of proinflammatory cytokines such as
interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha
(TNFα) in monocytes [4, 5]. Proinflammatory responses
are tightly controlled by concomitant induction of anti-
inflammatory mediators, such as IL-1ra, which competes
with IL-1 for binding to the IL-1 receptor 1 [6], and IL-10,
which is produced by monocytes at later time points after
stimulation and downregulates TNFα production [7].
There are some reports that showed enhanced transcrip-
tion and protein expression of inflammation-associated
genes in blood monocytes of patients with AS, suggesting
aberrant activation or disturbed responsiveness of mono-
cytes in patients with axSpA [8, 9].
To further decipher potential involvement of mono-
cytes in the pathogenesis of axSpA, we studied here the
phenotype and function of monocytes from patients with
axSpA. We performed a phenotypic analysis of mono-
cytes and determined their spontaneous and TLR and
NOD ligand-induced cytokine production.
Methods
Study subjects
Peripheral venous whole blood was collected in hepari-
nised Vacutainer tubes (BD, Heidelberg, Germany) from
29 healthy donors (15/29 male, mean age of 35.3 ±
8.3 years) and from 57 patients with axSpA (39/57 male,
mean age of 38.0 ± 10.6 years) meeting the Assessment
of Spondyloarthritis International Society criteria for
axSpA, of whom 39 patients (68.4 %) fulfilled the modi-
fied New York criteria for diagnosis of AS. Eleven pa-
tients (2/11 male, mean age of 59.7 ± 18.8 years) with
rheumatoid arthritis (RA) were included as inflamma-
tory controls. The number of patients and controls used
for individual parts of the study (phenotypic analysis and
cytokine analysis) is stated in each figure legend. Fifty-
three (92.9 %) of the 57 patients with axSpA were HLA-
B27-positive. Thirty-four patients with axSpA received
conventional treatment with continuous or on-demand
non-steroidal anti-inflammatory drugs (NSAIDs), and 23
patients received TNFα inhibitors. None of the patients
with axSpA received disease-modifying anti-rheumatic
drugs (DMARDs). Ten out of eleven patients with RA
received prednisolone, eight out of 11 received synthetic
DMARD therapy (four methotrexate, two hydroxychlor-
oquine, one sulfasalacine, and one methotrexate plus
sulfasalacine), and two patients received treatment with
biologics (one TNFα inhibitor and one anti-IL-6 recep-
tor antibody). Disease activity was determined according
to the Bath ankylosing spondylitis disease activity index
(BASDAI) [10]. C-reactive protein (CRP) was determined
at the routine clinical laboratory of the Charité.The study was approved by the local ethical commis-
sion of the Charité. All patients and control subjects
gave consent to the study.
Phenotypic characterization of peripheral blood monocytes
To analyse the expression of phenotypic surface markers,
2 ml of heparinized whole blood was incubated with 8 ml
of erythrocyte lysing buffer (Qiagen, Hilden, Germany) on
ice to lyse erythrocytes. The remaining cells were stained
with the respective antibodies against CD14 (clone M5E2
PerCPcy5.5; BD), CD16 (clone eBioCB16 APC; ebioscience,
Frankfurt, Germany), HLA-DR (clone L243 fluorescein
isothiocyanate (FITC); BD Heidelberg, Germany), CD64
(clone 10.1 PE; Dako, Glostrup, DK), CD80 (clone 2D10
PE; biolegend, San Diego, CA, USA), CD115 (clone 12-
3A3-1B10 PE; ebioscience), and CD163 (clone GHI/61PE;
BD). For analysis of TLR expression, 50 μl of heparinized
whole blood was incubated at room temperature with the
respective antibodies against TLR1, i.e., CD281 (clone
GD2.F4 TLR-1), TLR2, i.e., CD282 (clone TL2.1 TLR-2),
and TLR4, i.e., CD284 (clone HTA125 TLR-4; all PE;
ebioscience) in the dark for 15 min. Afterwards, erythro-
cytes were lysed with fluorescence-activated cell sorting
(FACS) lysing solution (BD) and leukocytes were analysed
by flow cytometry by using a FACS Calibur from Becton
Dickinson (San Jose, CA, USA) and FlowJo 7.6.4 Software.
In vitro stimulation of whole blood with Toll-like receptor
and nucleotide-binding oligomerization domain ligands
and intracellular cytokine detection
Heparinized peripheral blood (1 ml) was stimulated for
5 h without or with the TLR 1/2 ligand PAM3CSK4
(5 μg/ml), the TLR 2/6 ligand fibroblast-stimulating
lipopeptid-1 (FSL-1; 1 μg/ml), the TLR 4 ligand lipopoly-
saccharide (LPS) (Escherichia coli O111:B4; 100 ng/ml),
and the NOD2 ligand muramyl dipeptide (MDP) (2.5 μg/
ml). All stimulants were purchased from invivoGen (San
Diego, CA, USA).
To prevent cytokine secretion, 10 μg/ml brefeldin A
(BFA) (Sigma-Aldrich, Steinheim, Germany) was added
for the last 3 h of stimulation. After stimulation, erythro-
cytes were lysed with FACS lysing solution and the
remaining cells were fixed by 2 % paraformaldehyde
(Roth, Karlsruhe, Germany). Intracellular cytokines and
CD68 were stained after permeabilization in 0.5 % sap-
onin/phosphate-buffered saline buffer (Sigma-Aldrich,
Steinheim, Germany) by using the following antibodies:
anti-CD68-PerCPcy5.5 (clone Y1/82A; biolegend), anti-
IL-12/23p40 (clone eBioHP40; e-bioscience, Frankfurt,
Germany), anti-TNFα-FITC (clone Mab11; BD), anti-IL-
1β-Alexa Fluor 647 (clone JK1B-1; biolegend), anti-IL-6-
FITC (clone MQ2-13A5; BD), and anti-IL-1ra-PE (clone
AS17; BD). Cytokine expression was detected on a cellu-
lar level by using flow cytometric analysis. CD68 was
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 3 of 12used for identification of monocytes after stimulation,
which yielded better separation of monocytes than CD14
after stimulation.
In vitro stimulation of whole blood with Toll-like receptor
and nucleotide-binding oligomerization domain ligands
and detection of interleukin-10 production by
enzyme-linked immunosorbent assay
To determine IL-10 production, heparinised whole blood
was mixed 1:2 with RPMI supplemented with 10 % fetal
calf serum and stimulated without and with the respective
TLR and NOD ligands for 18 h. Supernatants were har-
vested by centrifugation, snap-frozen, and stored at −20 °C
until measurement of IL-10 by enzyme-linked immuno-
sorbent assay (ELISA) (BD OptEIA, Heidelberg, Germany).
Statistical analysis
Statistical analysis was performed by using GraphPad
Prism 5 software (GraphPad Inc., La Jolla, CA, USA)
and SPSS 19 software (IBM, Ehningen, Germany). Data
are shown as individual measurements and medians.
Non-parametric tests (Mann–Whitney U test and
Kruskal-Wallis test and Dunn’s post test) were used for
comparisons between groups. For variance analysis, we
log-transformed data with uneven distribution and used
linear regression analysis for metric variables and ana-
lysis of variance (ANOVA) for categorical variables.
Results
Expansion of classic monocytes in the peripheral blood of
patients with axial spondyloarthritis
To analyse the distribution of monocyte subsets (i.e.,
classic, intermediate, and non-classic monocytes) within
the peripheral blood of axSpA patients in comparison
with healthy controls and RA patients as an inflamma-
tory control, monocytes were gated according to forward
and side scatter and expression of HLA-DR (Fig. 1a). In
patients with axSpA, the percentage of classic mono-
cytes (CD14++CD16−) was significantly higher than in
healthy controls (median of 90.5 % versus 80.4 %, P <
0.05; Fig. 1b) whereas intermediate (CD14++CD16+) and
non-classic (CD14+CD16+) subsets were reduced in pa-
tients with axSpA (Fig. 1b). In patients with RA, non-
classic monocytes were also reduced whereas differences
in classic and intermediate monocyte subsets were not
significantly different from controls. Subanalysis of axSpA
patients grouped according to treatment into patients with
conventional treatment (i.e., on demand or continuous
NSAID treatment) or treatment with biologics showed sig-
nificantly lower frequencies of intermediate CD14++CD16+
monocytes in patients under conventional as well as in
patients treated with biologics compared with healthy con-
trols, whereas the difference in frequencies of CD14++
CD16− monocytes reached statistical significance only inpatients under standard therapy compared with healthy pa-
tients (P < 0.01) but not in patients under biological treat-
ment (Fig. 1c).
The expression of HLA-DR as an antigen-presenting
molecule, CD80 as a co-stimulatory molecule, CD163 as
a scavenger receptor, CD64 as the Fc receptor, or CD115
as an activation marker on monocytes showed no differ-
ence between axSpA patients and controls (P > 0.05; data
not shown).
In vivo pre-activation of monocytes of axial
spondyloarthritis patients according to proinflammatory
cytokine production
To determine spontaneous as well as TLR and NOD
ligand-induced production of cytokines by monocytes,
we incubated whole blood of 42 patients with axSpA (32
male, 10 female; mean age of 37.2 ± 9.8 years), 8 patients
with RA (2 male, 6 female; mean age of 59.7 ± 18.8 years;
all patients on prednisolone and DMARD treatment, no
treatment with biologics), and 26 controls (13 male; 13
female; mean age of 35.4 ± 7.1 years) without any stimu-
lator or added 2.5 μg/ml MDP (NOD-2 ligand), 100 ng/
ml LPS (TLR4 ligand), 1 μg/ml FSL-1 (TLR2/6 ligand),
or 5 μg/ml PAM3CSK4 (TLR1/2 ligand). Cytokine ex-
pression was determined in monocytes which were iden-
tified according to CD68 expression (Fig. 2a).
The percentage of monocytes spontaneously produ-
cing IL-1β was significantly higher in axSpA patients
compared with healthy controls (Fig. 2b). A similar non-
significant trend toward higher production was observed
for IL-6 and TNFα production in patients with axSpA,
whereas the IL-12/23p40 production was not increased.
Stimulation with MDP and also stimulation with FSL-
1 elicited a higher cytokine production by monocytes,
particularly of IL-1β, but also to lesser extent of IL-6
and TNFα, in patients with axSpA (Fig. 2b). For in-
stance, after MDP stimulation, 19.2 % (median) of the
monocytes of patients with axSpA versus 8 % of mono-
cytes of healthy controls (P < 0.01) produced IL-1β. In
contrast, IL-12/23 p40 production by monocytes was
low (i.e., below 5 %) after MDP and FSL stimulation and
was without difference between axSpA patients and
healthy controls. In contrast, patients with RA did not
show an elevated spontaneous or MDP- or FSL-induced
production of proinflammatory cytokines, despite a min-
imal but significant increase in the percentage of IL-12/
23p40-producting monocytes in unstimulated cultures.
In contrast, no difference was observed between axSpA
patients and controls in IL-1β and TNFα production in
response to LPS, which elicited the highest cytokine re-
sponse in monocytes. In patients with axSpA, more than
80 % of blood monocytes produced IL-1β in response to
LPS and about 60 % produced TNFα, which was not
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Fig. 1 (See legend on next page.)
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Fig. 1 Elevated percentage of classic monocytes in patients with axial spondyloarthritis (axSpA). a The percentage of classic CD14++CD16− (M1),
intermediate CD14++CD16+ (M2), and non-classic CD14+CD16+ (M3) monocytes was determined by fluorescence-activated cell sorting in whole
blood of controls, patients with axSpA, and patients with rheumatoid arthritis (RA). The percentage of classic, intermediate, and non-classic
monocytes was determined among monocytes which were gated according to forward (FSC) and side (SSC) scatter (R1) and HLA-DR expression
(R2). b The percentage of classic, intermediate, and non-classic monocytes (individual measurements and median) is shown from measurements
in 12 controls (C), 20 patients with axSpA (SpA), and 12 patients with RA (RA). *P < 0.05, **P < 0.01 (Kruskal-Wallis test and Dunn’s post test). c The
percentage of the respective populations in axSpA patients separated into patients under conventional treatment (SpA CT) (n = 12) and patients
receiving biologics (i.e., tumor necrosis factor inhibitors) (SpA BT) (n = 8) compared with controls (c). *P < 0.05, **P < 0.01 (Kruskal-Wallis test and
Dunn’s post test). FITC fluorescein isothiocyanate
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 5 of 12elicited higher responses than MDP, FSL-1, or PAM3CSK4
as indicated by the higher mean fluorescence intensity of
the IL-1β staining (Fig. 2a).
However, LPS stimulation resulted in significantly less
IL-6-producing monocytes in axSpA patients compared
with controls (median of 63.2 % versus 72.1 %; P < 0.01;
Fig. 2b). Also, in patients with RA, LPS-induced IL-6
and even TNFα production was reduced in comparison
with healthy controls (Fig. 2b). No significant difference
between axSpA patients and controls was found in mono-
cytic cytokine production in response to PAM3CSK4
stimulation (Fig. 2b).
The elevated spontaneous and MDP, and FSL-1,
induced proinflammatory cytokine production by mono-
cytes of patients with axSpA suggests in vivo pre-
activation of monocytes in these patients.Elevated frequency of monocytes spontaneously
producing interleukin-1 receptor antagonist in axial
spondyloarthritis and rheumatoid arthritis patients
To determine whether the preactivation of monocytes in
patients with axSpA is counterbalanced by an induction
of anti-inflammatory mediators, we analysed the produc-
tion of IL-1ra and IL-10. IL-1ra was detected by intracel-
lular staining and FACS, whereas IL-10 which is induced
at later time points after activation was measured by
ELISA in the supernatant of whole blood stimulations
performed in the absence of BFA. (Such cultures were
performed only in axSpA patients and controls.)
The percentage of monocytes spontaneously produ-
cing IL-1ra was significantly elevated in axSpA patients
but also RA patients compared with healthy controls
(Fig. 3a). In contrast, no difference was found after stimu-
lation with the different stimuli in the percentage of IL-
1ra-producing monocytes between axSpA or RA patients
and controls.
The IL-10 production induced by LPS was significantly
lower in axSpA patients compared with controls (me-
dian of 1860 versus 3314 pg/ml; P < 0.05). In contrast,
no difference was found in spontaneous or MDP-, FSL-1-,
or PAM3CSK4-induced IL-10 production between axSpA
patients and controls (Fig. 3).Analysis of association of monocytic cytokine production
with clinical parameters and treatment in patients with
axial spondyloarthritis
To determine the association between cytokine production
and the state of disease progression according to the
presence of radiographic sacroiliitis or the treatment, we
log-transformed the data of patients with axSpA and
performed a univariate variance analysis. This analysis
(ANOVA) revealed association of spontaneous cytokine
production (IL-1β, P = 0.009; IL-6, P = 0.03; TNFα,
P = 0.012) and FSL-1-induced IL-6 production (P = 0.007)
with therapy—conventional treatment versus treatment
with biologics (i.e., TNFα inhibitors)—but no association
with disease state (i.e., presence of radiographic sacroiliitis).Monocytic pre-activation is confined to axial
spondyloarthritis patients under conventional treatment
As the previous analysis suggested an impact of the ther-
apy on the cytokine responses by monocytes, we per-
formed a subanalysis of the data by stratifying the axSpA
patients according to therapy into patients receiving
conventional treatment and patients receiving TNFα in-
hibitors. This subanalysis revealed that elevated spontan-
eous production of IL-1β, IL-6, and TNFα was confined
to axSpA patients under conventional treatment (Fig. 4).
In this group, the percentage of monocytes spontan-
eously producing IL-1β and TNFα was significantly
higher than in patients under TNFα inhibitor (i.e., bio-
logical treatment) (P < 0.05).
Also, the enhanced production of proinflammatory
cytokines in response to MDP and FSL-1 was restricted
to the group of patients under conventional treatment
(Fig. 4). In this group of patients, the percentage of
monocytes producing IL-1β and IL-6 after MDP and
FSL-1 stimulation was significantly higher than in con-
trols even after subtraction of the percentage of mono-
cytes spontaneously producing these cytokines (data not
shown). In contrast, no difference was found between
patients under conventional treatment and patients
under TNFα inhibitor treatment in the percentage of



























































































































































Fig. 2 (See legend on next page.)
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Fig. 3 a Elevated spontaneous production of interleukin-1 receptor antagonist (IL-1ra) by monocytes of patients with axial spondyloarthritis (axSpA)
and rheumatoid arthritis (RA). The percentage of IL-1ra-producing monocytes among CD68+ monocytes was determined as in Fig. 2. The percentage
of cytokine-positive cells (individual measurement and median) in response to the different stimuli in controls (C) (n = 26), patients with axSpA (SpA)
(n = 42), and patients with RA (RA) (n = 8) is given. **P < 0.01 (Kruskal-Wallis test and Dunn’s post test). Whole blood of patients with axSpA (SpA)
(n = 26) and controls (C) (n = 13) was stimulated without or with indicated stimulators for 18 h. b IL-10 was measured in the supernatant by
enzyme-linked immunosorbent assay. *P < 0.05 (Mann–Whitney U test). FSL fibroblast-stimulating lipopeptid-1, LPS lipopolysaccharide, MDP
muramyl dipeptide, PAM PAM3CSK4, w/o without
(See figure on previous page.)
Fig. 2 Elevated spontaneous and muramyl dipeptide (MDP)-induced proinflammatory cytokine production by monocytes from patients with axial
spondyloarthritis (axSpA). Cytokine production by monocytes after stimulation of whole blood without (unstimulated) or with MDP, lipopolysaccharide
(LPS), fibroblast-stimulating lipopeptid-1 (FSL), and PAM3CSK4 (PAM) for 5 h with brefeldin A added for the last 3 h. Cytokine production was analysed
after intracellular staining by fluorescence-activated cell sorting. Monocytes were identified according to CD68 expression. a A representative example
of cytokine production of CD68+ monocytes of a patient with axSpA in whole blood without stimulation and stimulation with the respective stimuli
is shown. b The percentage of cytokine-positive cells among CD68+ monocytes (individual measurement and median) in response to the different
stimuli in controls (C) (n = 26), patients with axSpA (SpA) (n = 42), and patients with rheumatoid arthritis (RA) (n = 8) is given. *P < 0.05; **P < 0.01
(Kruskal-Wallis test and Dunn’s post test). IL interleukin, TNFα tumour necrosis factor alpha
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Fig. 4 Disturbed cytokine responses are found predominately in axial spondyloarthritis patients under conventional treatment. Subanalysis of
monocytic cytokine production (Fig. 3) in patients stratified according to treatment into a group of patients receiving conventional treatment
spondyloarthritis (CT) (n = 20) and patients receiving biological treatment (i.e., TNF inhibitor treatment) (BT) (n = 12) compared with healthy controls (C)
(n = 17). *P < 0.05; **P < 0.01 (Kruskal-Wallis test and Dunn’s post test). FSL fibroblast-stimulating lipopeptid-1, IL interleukin, LPS lipopolysaccharide, MDP
muramyl dipeptide, TNFα tumour necrosis factor alpha
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 8 of 12Interestingly, LPS-induced cytokine responses did not
differ between both groups of patients; that is, IL-6
(Fig. 4) and IL-10 production (data not shown) was re-
duced in both groups of patients compared with controls
(P < 0.05). Moreover, there was no difference in the per-
centage of IL-1ra-producing monocytes between patientsunder conventional treatment and patients under TNFα
inhibitor treatment (data not shown).
To determine the association between monocytic cyto-
kine production and clinical parameters such as inflamma-
tory parameters, presence of radiographic sacroiliitis, and
disease activity in patients with axSpA under conventional
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 9 of 12treatment, we performed an ANOVA and linear regression
analysis. In this analysis, monocytic cytokine production
(unstimulated and MDP-, LPS-, and FSL-1-stimulated)
was not associated with CRP, but a strong association of
monocytic cytokine production was observed with BAS-
DAI (Table 1).Difference in cytokine production by monocytes is not
due to differences in Toll-like receptor expression in
patients with axial spondyloarthritis
To determine whether differences in TLR ligand-induced
monocytic cytokine production between axSpA patients
and controls are due to differences in expression of TLR
ligands, we analysed the expression of TLR 1, 2, and 4 on
monocytes. No difference was found in surface expressionTable 1 P values from univariate analysis of variance between
clinical variables and cytokine responses in axial spondyloarthritis




IL-1 0.980 0.539 0.011
IL-6 0.604 0.829 0.025
TNF 0.856 0.984 0.006
IL-1RA 0.299 0.449 0.181
IL-10 0.488 0.584 0.318
MDP
IL-1 0.300 0.126 0.040
IL-6 0.693 0.698 0.034
TNF 0.439 0.963 0.007
IL-1RA 0.098 0.433 0.010
IL-10 0.634 0.812 0.177
LPS
IL-1 0.888 0.584 0.005
IL-6 0.546 0.625 0.029
TNF 0.692 0.516 0.001
IL-1RA 0.543 0.744 0.048
IL-10 0.691 0.742 0.010
FSL
IL-1 0.492 0.470 0.642
IL-6 0.389 0.483 0.669
TNF 0.861 0.918 0.669
IL-1RA 0.227 0.390 0.040
IL-10 0.714 0.199 0.037
CRP C-reactive protein, BASDAI Bath ankylosing spondylitis disease activity
index, IL interleukin, TNF tumor necrosis factor, MDP muramyl dipeptide,
LPS lipopolysaccharide, FSL fibroblast-stimulating lipopeptidof either of the receptors on monocytes in axSpA patients
and RA patients compared with controls (Fig. 5).
Discussion
In this study, we observed an elevated frequency of clas-
sic (i.e., CD14++CD16−) monocytes and a reduction in
non-classic (i.e., CD14+CD16+) monocytes in peripheral
blood of patients with axSpA and this is in accordance
with a study by Surdacki et al. [11]. TNFα inhibitor
treatment did not reverse these phenotypic differences.
In patients with RA, we also observed a trend toward an
increase of classic monocytes at the expense of non-
classic monocytes. This is in line with data from Klimek
et al. [12] but in contrast to other studies which reported
an expansion of CD14/CD16 double-positive (i.e., non-
classic) monocytes in RA [13, 14]. These discrepancies
are most likely related to differences in therapy; in
particular, glucocorticoid therapy has been described to
deplete CD14+CD16+ monocytes [15]. In patients with
Crohn’s disease, an expansion of non-classic monocytes
was described [16]. It was suggested that the imbalance
between monocyte subsets in patients with Crohn’s dis-
ease is due to recruitment of the classic monocytes, which
are more migratory than the non-classic monocytes, to
sites of inflammation [16]. Therefore, the difference be-
tween axSpA and Crohn’s disease may be caused by differ-
ences in the extent of local inflammation which controls
recruitment of monocytes. On the other hand, HLA-B27
could also affect the differentiation of monocyte subsets
and promote the differentiation of classic monocytes.
Thiesen et al. analysed cytokine production of sorted
human monocyte subsets and found that classic mono-
cytes, though considered more phagocytic and less in-
flammatory, produced higher levels of proinflammatory
cytokines than the non-classic monocytes [16]. Interest-
ingly, we observed enhanced spontaneous as well as
MDP- and FSL-1-induced production of proinflamma-
tory cytokines in patients with axSpA and, according to
the data by Thiesen et al., this could be related to the ex-
pansion of classic monocytes.
The enhanced cytokine production by monocytes of
patients with axSpA in particular to suboptimal stimuli
such as MDP and FSL-1, which require co-activating
signals such as ineffective doses of LPS [17] or low levels
of cytokines, suggests that monocytes of patients with
axSpA are pre-activated in vivo. This is also suggested
by mRNA expression profiles showing enhanced IL-1 re-
ceptor expression in blood cells of patients with axSpA
[18] and by results of protein profiling of monocytes of
axSpA patients that showed enhanced expression of pro-
teins involved in TLR signaling, leukocyte extravasation,
and other inflammatory pathways [8]. Genome associ-
ation studies [19] and experimental [20] and clinical [21]


















































































Fig. 5 No difference in Toll-like receptor (TLR) 1, 2, and 4 expression on CD14+ monocytes between axial spondyloarthritis patients and controls.
The expression of TLR-1, TLR-2, and TLR-4 on monocytes was determined in healthy controls (C) (n = 16), patients with axial spondyloarthritis
(SpA) (n = 22), and patients with rheumatoid arthritis (RA) (n = 9) by surface staining and fluorescence-activated cell sorting and is given as the
mean fluorescence intensity (MFI). Monocytes were identified according to CD14 expression
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 10 of 12in axSpA. However, the production of IL-12/23p40 pro-
duction was rather low in peripheral blood monocytes in
our study and with no difference between axSpA pa-
tients and controls. Even after strong stimulation with
LPS, only about 5 % of the monocytes produced IL-12/
23p40, suggesting that monocytes are not a major source
of this cytokine. In fact, our own analysis of the bone
marrow of facet joints of patients with AS revealed
myeloperoxidase-positive cells and, to a lesser extent,
macrophages and dendritic cells as sources of IL-23 [22].
In contrast to the enhanced cytokine responses to
MDP and FSL-1, cytokine production in response to
LPS was, at least partially, reduced in patients with axSpA.
Reduced LPS responses are observed in endotoxin toler-
ance which is induced by pre-exposure of monocytes to
low doses of LPS. However, the suppression of proinflam-
matory cytokine responses by monocytes of patients with
axSpA is rather minor and accompanied by a strong sup-
pression of anti-inflammatory IL-10 production, whereas
the state of endotoxin tolerance and monocyte paralysis, as
for instance observed in patients with sepsis, is character-
ized by a strongly suppressed proinflammatory response
and partly preserved IL-10 production [23]. Thus, the de-
cent reduction of cytokine responses to LPS which is the
strongest of the tested stimuli may indicate exhaustion of
monocytes after pre-activation rather than tolerization.
The enhanced spontaneous production of cytokines
was restricted to axSpA patients under conventional
treatment and is not found in axSpA patients under
TNFα inhibitor treatment or in RA patients. However,
LPS-induced IL-6 and IL-10 production was also re-
duced in axSpA patients who received TNFα inhibitor.
This could be attributable to the presence of TNFα inhibi-
tors in the whole blood stimulation which may neutralize
some autocrine effects of TNFα produced during early ac-
tivation. In particular, IL-10 depends on autocrine produc-
tion of TNFα [7]. Also, in patients with RA, LPS-induced
production of IL-6 and TNFα was reduced and this may
also be related to glucocorticoid therapy [24].Differences in cytokine responses to TLR ligands may
be caused by differential expression of TLRs. In fact, en-
hanced expression of TLR 4 on blood monocytes has
been described in patients with SpA [25]. However, in
our study, no differences were found in the expression
of TLR 1, 2, and 4 in axSpA patients compared with
controls and this might be due to technical differences
as we analysed expression in whole blood as compared
with isolated peripheral blood mononuclear cells and
used a different gating strategy.
Interestingly, stimulation of bone marrow cells and
splenocytes from HLA-B27/huβ2m transgenic rats with
TNFα [26] or zymosan or Mycobacterium tuberculosis
also resulted in elevated production of IL-1α and IL-1β
compared with control rats, indicating that the enhanced
responsiveness of axSpA patients to bacterial triggers
may be related to HLA-B27. On the other hand, the ex-
pansion of classic monocytes and in vivo pre-activation
of monocytes in patients with axSpA could also be the
result of in vivo activation by cytokines released by local
inflammation or by bacterial components such as LPS
which may translocate during intestinal inflammation as
mucosal inflammation is a common feature in axSpA.
Thus, about 5 % of patients with AS also suffer from
overt inflammatory bowel disease [27] and about 50 %
show microscopic gut lesions in the absence of gastro-
intestinal discomfort [28].
Delineation of potential triggers of the spontaneous
cytokine production is difficult since cellular responses
of monocytes to LPS and cytokines such as TNFα are
strongly overlapping [29]. Only some genes such as
apoptosis-related genes are selectively induced in mono-
cytes by LPS in vitro [29] and analysis of their expression
might provide clues on the activating signal of monocytes
in patients with axSpA.
TNFα inhibitor treatment of axSpA normalized the
functional state of monocytes as elevated cytokine re-
sponses were confined to axSpA patients under conven-
tional treatment. The fact that MDP- and FSL-1-induced
Conrad et al. Arthritis Research & Therapy  (2015) 17:179 Page 11 of 12cytokine production was unaffected under TNFα inhibi-
tor treatment suggests that the effect of TNFα inhibitor
treatment is an in vivo effect rather than an in vitro effect.
Thus, the TNFα inhibitor treatment may interfere with the
triggers of monocytic cytokine production such as local
cytokine production or bacterial antigen translocation.
Interestingly, we found that spontaneous MDP- and
LPS-induced production of cytokines correlated with
disease activity. As CRP correlated neither with BASDAI
nor with the monocytic cytokine production, monocyte
activation might be a more sensitive indicator of inflam-
mation than CRP. However, the monocytic pre-activation,
particularly the spontaneous production of IL-1β as well
as IL-6, does not seem to be directly pathogenic as block-
ade of IL-1 [30] as well as IL-6 [31] is of limited or no effi-
cacy in reducing disease activity in AS. The enhanced
IL-1β and IL-6 production by monocytes rather seems to
be an indicator of systemic innate immune activation
while other immune functions of monocytes or other cell
types may exert the pathogenic effects.
Conclusions
This study reveals in vivo pre-activation of monocytes in
axSpA patients indicated by enhanced spontaneous as
well as MDP- and FSL-induced cytokine production by
monocytes which correlates with BASDAI. This in vivo
pre-activation is confined to patients under conventional
therapy and reverted under TNFα inhibitor treatment.
Further work should delineate the triggers of this sys-
temic activation of innate cells.
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